Investors may have missed OncoMed Pharmaceuticals (OMED) in the flurry of biotech IPOs this year, but last week's pop was more than enough to raise a few eyebrows. Shares soared more than 80% after the company announced a deal with big biotech Celgene (CELG). In the following video, analysts Simon Erickson and Max Macaluso discuss the details of the deal, what it means for both OncoMed and Celgene, and whether partnerships like this will be a continuing trend in the biotech space.